AbbVie is a pharmaceutical company that is a recognized leader in the immunology market, whose drugs play key roles in the treatment of plaque psoriasis ... the treatment of diffuse large B ...

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B ... for moderate to severe plaque psoriasis, and Ipsen’s Decapeptyl ...

chronic plaque psoriasis, endometrial cancer, gastric cancer, head and neck squamous cell carcinoma, melanoma, colorectal cancer, triple negative breast cancer, small cell lung cancer, urothelial ...

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.

That’s because certain genes play a role. Psoriasis is a skin disease that affects about 8 million Americans. It comes in several forms. Plaque psoriasis is the most common. Plaque psoriasis ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...

One study found that pain was self-reported as a symptom in over 4 in 10 people with plaque psoriasis. For some others, the same immune system that causes plaque on your skin could instead inflame ...

President-elect Donald Trump won't have to walk beneath a plaque honoring Jan. 6 heroes when he takes the oath of office on the west front of the Capitol Monday. That's because more than four ...